Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis

By Taguchi I.   Oka K.   Kitamura K.   Sugiura M.   Oku A.   Matsumoto M.  

Inflammation Research, Vol. 48, Iss. 7, 1999-07 ,pp. : 380-385

Springer Publishing Company

Access to resources Recommend Favorite

Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, reduces neuronal damage following cerebral ischemia in the gerbil

By Kato H.   Araki T.   Itoyama Y.   Kogure K.  

European Journal of Pharmacology, Vol. 272, Iss. 1, 1995-01 ,pp. : 107-110

Elsevier

Access to resources Recommend Favorite

Involvement of μ-Opioid Receptor in Methamphetamine-Induced Behavioral Sensitization

By  

Current Neuropharmacology, Vol. 9, Iss. 1, 2011-03 ,pp. : 215-218

Bentham Science Publishers

Access to resources Recommend Favorite

Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol

By Sasaki H.   Hashimoto K.   Inada T.   Fukui S.   Iyo M.  

European Journal of Pharmacology, Vol. 282, Iss. 1, 1995-08 ,pp. : 71-76

Elsevier

Access to resources Recommend Favorite

Roles of adenosine A 1 and A 2A receptors in the expression and development of methamphetamine-induced sensitization

By Shimazoe T.   Yoshimatsu A.   Kawashimo A.   Watanabe S.  

European Journal of Pharmacology, Vol. 388, Iss. 3, 2000-02 ,pp. : 249-254

Elsevier

Access to resources Recommend Favorite